
Lipum Q1 - Initiating preparations for phase II

Redeye provides a research update following the Q1 report published by Lipum earlier today. While the report did not include any major surprises, we focus on the recent events surrounding the company. With a bolstered cash position following the recent rights issue, Lipum is set to initiate preparations for the upcoming phase II trials. We reiterate our valuation of Lipum with a base case of SEK15.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lipum Q1 - Initiating preparations for phase II](#)